Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
Anaplastic large cell lymphoma (ALCL) positive for anaplastic lymphoma kinase (ALK) is a defined subtype with distinct biological characteristics. Confirmation of ALK positivity is central to establishing the appropriate treatment pathway for this presentation.
Clinical scenario
This protocol applies to anaplastic large cell lymphoma that is ALK-positive. The presence of ALK positivity is the key determinant directing clinical decision-making in this setting.
Treatment approach
An antibody-drug conjugate has a defined, evidence-graded role in the management of this presentation, contingent on prior treatment history.
The full regimen, eligibility criteria, sequencing, and evidence grading are available in the complete protocol.
References
DOI: 10.1016/j.annonc.2025.07.014
First-line treatment of ALK-positive ALCL:
For patients with r/r ALK-positive ALCL, BV is recommended if not received as first-line therapy [III, A].
View source ↗